PE20161344A1 - Determinantes de respuesta del cancer a la inmunoterapia - Google Patents

Determinantes de respuesta del cancer a la inmunoterapia

Info

Publication number
PE20161344A1
PE20161344A1 PE2016000989A PE2016000989A PE20161344A1 PE 20161344 A1 PE20161344 A1 PE 20161344A1 PE 2016000989 A PE2016000989 A PE 2016000989A PE 2016000989 A PE2016000989 A PE 2016000989A PE 20161344 A1 PE20161344 A1 PE 20161344A1
Authority
PE
Peru
Prior art keywords
antigen
composition
determinants
immunotherapy
cancer
Prior art date
Application number
PE2016000989A
Other languages
English (en)
Spanish (es)
Inventor
Timothy Chan
Jedd Wolchok
Charen Alexandra Snyder
Vladimir Makarov
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of PE20161344A1 publication Critical patent/PE20161344A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PE2016000989A 2014-01-02 2014-12-23 Determinantes de respuesta del cancer a la inmunoterapia PE20161344A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461923183P 2014-01-02 2014-01-02
US201462066034P 2014-10-20 2014-10-20
US201462072893P 2014-10-30 2014-10-30

Publications (1)

Publication Number Publication Date
PE20161344A1 true PE20161344A1 (es) 2016-12-23

Family

ID=53494217

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016000989A PE20161344A1 (es) 2014-01-02 2014-12-23 Determinantes de respuesta del cancer a la inmunoterapia

Country Status (15)

Country Link
US (1) US20160326597A1 (enExample)
EP (1) EP3090066A4 (enExample)
JP (1) JP2017504324A (enExample)
KR (1) KR20160102314A (enExample)
CN (1) CN106164289A (enExample)
AU (1) AU2014374020A1 (enExample)
BR (1) BR112016015399A2 (enExample)
CA (1) CA2935214A1 (enExample)
CL (1) CL2016001708A1 (enExample)
MX (1) MX2016008771A (enExample)
PE (1) PE20161344A1 (enExample)
PH (1) PH12016501329A1 (enExample)
RU (1) RU2707530C2 (enExample)
SG (2) SG10201805674YA (enExample)
WO (1) WO2015103037A2 (enExample)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
US20170313775A1 (en) 2014-11-13 2017-11-02 The Johns Hopkins University Checkpoint Blockade and Microsatellite Instability
MA40737A (fr) 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
WO2016146143A1 (en) 2015-03-16 2016-09-22 Amal Therapeutics Sa Cell penetrating peptides and complexes comprising the same
US20190099475A1 (en) 2015-04-08 2019-04-04 Nantomics, Llc Cancer neoepitopes
JP7236216B2 (ja) * 2015-04-23 2023-03-09 ナントミクス，エルエルシー がんのネオエピトープ
EP3294324A1 (en) 2015-05-13 2018-03-21 Agenus Inc. Vaccines for treatment and prevention of cancer
GB201516047D0 (en) * 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
KR20180083327A (ko) * 2015-10-12 2018-07-20 난토믹스, 엘엘씨 바이러스성 암 네오에피토프를 위한 조성물 및 방법
EP3362929B1 (en) * 2015-10-12 2020-08-12 Nantomics, LLC Viral neoepitopes and uses thereof
JP2018532736A (ja) * 2015-10-12 2018-11-08 ナントミクス，エルエルシー チェックポイント阻害物質への感受性を予測するｍｓｉおよびネオエピトープの探索のための系、組成物、および方法
EP3719143B1 (en) * 2015-10-23 2023-07-26 Novartis AG Method of deriving a value for percent biomarker positivity for selected cells present in a field of view
TWI733719B (zh) 2015-12-07 2021-07-21 美商河谷控股Ｉｐ有限責任公司 改善的組合物及用於新表位之病毒遞送的方法及其應用
US20170199961A1 (en) 2015-12-16 2017-07-13 Gritstone Oncology, Inc. Neoantigen Identification, Manufacture, and Use
CN108472350A (zh) * 2016-01-08 2018-08-31 瓦西博迪公司 新表位rna癌症疫苗
KR20180107257A (ko) 2016-02-19 2018-10-01 난트 홀딩스 아이피, 엘엘씨 면역원 조절 방법 (methods of immunogenic modulation)
KR102500659B1 (ko) 2016-02-29 2023-02-16 제넨테크, 인크. 암에 대한 치료 및 진단 방법
WO2017151517A1 (en) * 2016-02-29 2017-09-08 Foundation Medicine, Inc. Methods of treating cancer
JP6710004B2 (ja) * 2016-03-15 2020-06-17 Ｒｅｐｅｒｔｏｉｒｅ Ｇｅｎｅｓｉｓ株式会社 免疫療法のためのモニタリングまたは診断ならびに治療剤の設計
LT3429618T (lt) * 2016-03-16 2024-05-10 Amal Therapeutics Sa Imuninės sistemos patikros taško moduliatoriaus ir komplekso, apimančio į ląsteles prasiskverbiantį peptidą, krovinį ir tlr peptido agonistą, derinys, skirtas naudoti medicinoje
JP2019517557A (ja) * 2016-06-10 2019-06-24 アイオー セラピューティクス インコーポレイテッド 癌免疫療法のための受容体選択的レチノイドおよびレキシノイド化合物および免疫調節因子
US20190247435A1 (en) * 2016-06-29 2019-08-15 The Johns Hopkins University Neoantigens as targets for immunotherapy
WO2018055060A1 (en) 2016-09-21 2018-03-29 Amal Therapeutics Sa Fusion comprising a cell penetrating peptide, a multi epitope and a tlr peptide agonist for treatment of cancer
EP3516081A4 (en) * 2016-09-23 2020-07-29 Memorial Sloan Kettering Cancer Center DETERMINANTS OF CANCER RESPONSE TO IMMUNOTHERAPY
IL265759B2 (en) * 2016-10-06 2025-10-01 Genentech Inc Therapeutic and diagnostic methods for cancer
WO2018102613A2 (en) 2016-12-01 2018-06-07 Nantomics, Llc Tumor antigenicity processing and presentation
WO2018112449A2 (en) 2016-12-16 2018-06-21 Nant Holdings Ip, Llc Live cell imaging systems and methods to validate triggering of immune response
WO2018132753A1 (en) * 2017-01-13 2018-07-19 Nantbio, Inc. Validation of neoepitope-based treatment
ES2971298T3 (es) 2017-01-18 2024-06-04 Icahn School Med Mount Sinai Neoantígenos y usos de los mismos para el tratamiento del cáncer
WO2018146128A1 (en) * 2017-02-07 2018-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Detection of kit polymorphism for predicting the response to checkpoint blockade cancer immunotherapy
CA3056700A1 (en) * 2017-03-17 2018-09-20 Nantomics, Llc Liquid biopsy for cfrna
IL269026B2 (en) * 2017-03-31 2024-12-01 Bristol Myers Squibb Co Anti-pd-1 antibodies for treating tumors in high tumor mutational burden (tmb) patients
WO2018222433A2 (en) 2017-05-30 2018-12-06 Nant Holdings Ip, Llc Circulating tumor cell enrichment using neoepitopes
CN110996970A (zh) 2017-06-02 2020-04-10 亚利桑那州立大学董事会 创建个性化癌症疫苗的方法
US10311967B2 (en) * 2017-06-13 2019-06-04 Bostongene Corporation Systems and methods for generating, visualizing and classifying molecular functional profiles
GB201710815D0 (en) * 2017-07-05 2017-08-16 Francis Crick Inst Ltd Method
WO2019055618A1 (en) 2017-09-15 2019-03-21 Arizona Board Of Regents On Behalf Of Arizona State University METHODS OF CLASSIFYING RESPONSES TO ANTICANCER IMMUNOTHERAPY
KR20200059243A (ko) 2017-09-20 2020-05-28 리제너론 파마슈티칼스 인코포레이티드 패신저 유전자 돌연변이 부담이 높은 종양을 가진 환자에 대한 면역 치료요법
EP4226944A3 (en) * 2017-09-25 2023-10-25 Memorial Sloan Kettering Cancer Center Tumor mutational load and checkpoint immunotherapy
EP3688165A4 (en) 2017-09-25 2021-09-29 Nant Holdings IP, LLC VALIDATION OF THE PRESENTATION OF NEOEPITOPES
ES3029080T3 (en) 2017-10-10 2025-06-23 Seattle Project Corp Neoantigen identification using hotspots
KR20200064132A (ko) 2017-10-15 2020-06-05 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
EP3704268B1 (en) 2017-11-03 2025-01-22 Guardant Health, Inc. Normalizing tumor mutation burden
JP2021503077A (ja) * 2017-11-09 2021-02-04 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 細胞外小胞タンパク質、ならびに癌診断、療法に対する応答予測、および治療をするためのそれらの使用
US11885815B2 (en) 2017-11-22 2024-01-30 Gritstone Bio, Inc. Reducing junction epitope presentation for neoantigens
AU2018375008B2 (en) 2017-12-01 2024-06-27 Illumina, Inc. Methods and systems for determining somatic mutation clonality
CN108009400B (zh) * 2018-01-11 2018-07-06 至本医疗科技（上海）有限公司 全基因组肿瘤突变负荷预测方法、设备以及存储介质
US11414698B2 (en) * 2018-03-22 2022-08-16 Chang Gung Medical Foundation Chang Gung Memorial Hospital At Chiayi Method of quantifying mutant allele burden of target gene
US11065317B2 (en) 2018-04-26 2021-07-20 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
CN120193081A (zh) 2018-07-23 2025-06-24 夸登特健康公司 用于通过肿瘤分数和覆盖率调整肿瘤突变负荷的方法和系统
CN121354685A (zh) 2018-08-31 2026-01-16 夸登特健康公司 无细胞dna中的微卫星不稳定性检测
CN109371005B (zh) * 2018-11-12 2022-09-30 上海市东方医院（同济大学附属东方医院） 一种hla-0201限制性padi4表位多肽及其应用
EP3893932A4 (en) * 2018-12-12 2022-09-07 Medimmune, LLC BLOOD-BASED TUMORMUTATION LOAD AS A PREDICTOR OF OVERALL SURVIVAL IN NON-SMALL CELL LUNG CANCER
US20220081723A1 (en) * 2018-12-21 2022-03-17 Agency For Science, Technology And Research Method of predicting for benefit from immune checkpoint inhibition therapy
WO2020206127A1 (en) * 2019-04-05 2020-10-08 Illumina, Inc. Quantitative score of hla diversity
CN114245874A (zh) * 2019-05-24 2022-03-25 艾迪菲斯健康有限公司 用于癌症免疫疗法的精准医学方法
WO2021067550A1 (en) 2019-10-02 2021-04-08 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer
NL2024107B1 (en) * 2019-10-26 2021-07-19 Vitroscan B V Compositions for Patient Specific Immunotherapy
CN111088349B (zh) * 2020-02-14 2023-04-28 深圳市宝安区妇幼保健院 Kir3dl1基因分型引物组及其应用
US20230108284A1 (en) * 2020-03-23 2023-04-06 Koninklijke Philips N.V. Prediction of radiotherapy response for prostate cancer subject based on immune checkpoint genes
GB202007099D0 (en) 2020-05-14 2020-07-01 Kymab Ltd Tumour biomarkers for immunotherapy
WO2022009052A2 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
EP4000596A1 (en) * 2020-11-17 2022-05-25 The Boots Company plc Tetrapeptide and compositions comprising tetrapeptides
EP4000595A1 (en) * 2020-11-17 2022-05-25 The Boots Company plc Tetrapeptide and compositions comprising tetrapeptides
US20240192195A1 (en) * 2021-04-10 2024-06-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. A multiomic approach to modeling of gene regulatory networks in multiple myeloma
AU2021461416A1 (en) 2021-08-24 2024-02-22 BioNTech SE In vitro transcription technologies
WO2024083345A1 (en) 2022-10-21 2024-04-25 BioNTech SE Methods and uses associated with liquid compositions
WO2024216165A1 (en) 2023-04-12 2024-10-17 Icahn School Of Medicine At Mount Sinai Computational methods for selecting personalized neoantigen vaccines

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9826143D0 (en) * 1998-11-27 1999-01-20 Ludwig Inst Cancer Res Tumour rejection antigens
US9222938B2 (en) * 2001-12-04 2015-12-29 Michael Tainsky Neoepitope detection of disease using protein arrays
EP1814568A4 (en) * 2004-10-29 2009-08-12 Univ Southern California COMBINATION IMMUNOTHERAPY AGAINST CANCER WITH COSTIMULATORY MOLECULES
WO2008109075A2 (en) * 2007-03-05 2008-09-12 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to ctla-4 antagonists
EP2569633B1 (en) * 2010-05-14 2016-02-10 The General Hospital Corporation Compositions and methods of identifying tumor specific neoantigens
GB201103955D0 (en) * 2011-03-09 2011-04-20 Antitope Ltd Antibodies
WO2012159643A1 (en) * 2011-05-24 2012-11-29 Biontech Ag Individualized vaccines for cancer

Also Published As

Publication number Publication date
AU2014374020A1 (en) 2016-08-18
JP2017504324A (ja) 2017-02-09
SG10201805674YA (en) 2018-08-30
RU2016131207A (ru) 2018-02-07
CA2935214A1 (en) 2015-07-09
KR20160102314A (ko) 2016-08-29
MX2016008771A (es) 2016-12-20
WO2015103037A3 (en) 2015-11-05
US20160326597A1 (en) 2016-11-10
EP3090066A4 (en) 2017-08-30
CN106164289A (zh) 2016-11-23
SG11201605432RA (en) 2016-07-28
BR112016015399A2 (pt) 2017-10-24
PH12016501329A1 (en) 2016-10-03
RU2707530C2 (ru) 2019-11-27
RU2016131207A3 (enExample) 2018-06-22
CL2016001708A1 (es) 2017-03-17
WO2015103037A2 (en) 2015-07-09
EP3090066A2 (en) 2016-11-09

Similar Documents

Publication Publication Date Title
PE20161344A1 (es) Determinantes de respuesta del cancer a la inmunoterapia
CY1124771T1 (el) Αντισωματα εναντι-σορτιλiνης και μεθοδοι χρησης αυτων
CY1124190T1 (el) Anti-ctla4 μονοκλωνικο αντισωμα ή το θραυσμα δεσμευσης αντιγονου αυτου, φαρμακευτικη συνθεση και χρηση
CO2019000946A2 (es) Receptores de antígenos quiméricos dirigidos a bcma y métodos de uso de estos
PE20170125A1 (es) Receptor antigenico quimerico (car) que comprende un dominio de union de antigenos, el cual se une selectivamente a la region constante del tcr beta 1 (trbc1) o trbc2 de celulas t
CL2017001610A1 (es) Anticuerpos humanos para hemagglutinina de influenza
SA518391722B1 (ar) أجسام مضادة تستهدف شبيه مستقبل Fc5 وطرق استخدامها
PE20180480A1 (es) Anticuerpos de factor xi y metodos de uso
PE20170289A1 (es) Anticuerpos anti tigit
CO2017007619A2 (es) Anticuerpos humanos contra glicoproteína del virus ébola
MX376026B (es) Inmunoreceptores especificos de claudina-6 y epitopos de celulas t.
MX2022002364A (es) Anticuerpos anti-pd-l1.
PE20190970A1 (es) Anticuerpos anti-cd40 y sus usos
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
MX389021B (es) Inmunoreceptores especificos de claudina-18.2 y epitopos de celulas t.
MX375800B (es) Anticuerpos humanizados contra cd269 (bcma).
MX2017001011A (es) Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma.
MX2015013104A (es) Composiciones y métodos para la inmunoterapia.
PE20161392A1 (es) Combinacion de lenalidomida y constructo de polipeptido, y sus usos
PL422231A1 (pl) Komórki immunologiczne CAR do leczenia nowotworów
PE20171180A1 (es) Anticuerpos anti-pd-1 y sus metodos de uso
JO3791B1 (ar) تركيبات و طرق الأجسام المضادة المستهدفة لـ bmp6
PE20161032A1 (es) Anticuerpos anti-tau(ps422) humanizados y metodos de utilizacion
EA201791270A1 (ru) Модифицированные april-связывающие антитела
SG10201902924RA (en) Antibodies that bind ebola glycoprotein and uses thereof